文献速递脊柱关节炎

外周型脊柱关节炎患者阿达木单抗治疗后长期疗效与缓解预测因素:ABILITY-2研究3年结果

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2.
PubMed 文献 · RMD Open · 2018-02-26

ABILITY-2研究纳入165例外周型脊柱关节炎患者,先随机接受阿达木单抗40mg隔周一次或安慰剂治疗12周,随后进入144周开放标签延长期。1年和3年时分别有47%和39%的患者达到ASDAS非活动性疾病,36%和33%达到PSpARC缓解;第12周即达到ASDAS非活动性疾病或PSpARC缓解可显著预测1年、3年及持续缓解,而基线变量不能一致预测缓解。

要点

  • 3年时39%达ASDAS非活动性疾病,33%达PSpARC缓解。
  • 第12周达ASDAS非活动性疾病可预测1年、3年及持续缓解。
  • 第12周达PSpARC缓解可预测1年、3年及持续缓解。

核心结论

  • 在外周型脊柱关节炎患者中,阿达木单抗的早期应答而非基线人口学或疾病特征能更好地预测长期缓解。

研究设计与样本

  • 外周型脊柱关节炎患者随机接受阿达木单抗40mg隔周一次或安慰剂治疗12周,随后进行144周开放标签延长期(NCT01064856),共165例患者。

主要发现

  • 1年时47%的患者达到ASDAS非活动性疾病,3年时为39%。
  • 1年时36%的患者达到PSpARC缓解,3年时为33%。
  • 52%(86/165)的患者达到持续ASDAS非活动性疾病,42%(70/165)达到持续PSpARC缓解。
  • 第12周达到ASDAS非活动性疾病显著预测1年ASDAS非活动性疾病(OR 8.64,95%CI 2.97至25.14)、3年ASDAS非活动性疾病(OR 36.12,95%CI 2.29至569.08)及持续ASDAS非活动性疾病(OR 8.01,95%CI 2.47至25.97)。
  • 第12周达到PSpARC缓解一致预测1年PSpARC缓解(OR 6.47,95%CI 1.91至21.95)、3年PSpARC缓解(OR 15.66,95%CI 4.19至58.56)及持续PSpARC缓解(OR 20.27,95%CI 5.37至76.46)。

关键数值与推荐

  • 缓解评估采用外周型脊柱关节炎反应标准(PSpARC)和强直性脊柱炎疾病活动度评分非活动性疾病(ASDAS ID)。
  • 持续缓解定义为连续≥24周维持缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Describe efficacy and safety of 3 years of adalimumab treatment in patients with peripheral spondyloarthritis (pSpA) and identify predictors of remission. METHODS: Patients with pSpA were randomised to adalimumab 40 mg every other week or placebo for 12 weeks; a 144-week open-label extension followed (NCT01064856). Remission was assessed by the Peripheral SpA Response Criteria (PSpARC) and Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS ID). Logistic regression analyses were performed to determine predictors of remission at 1 and 3 years and sustained remission (≥24 consecutive weeks). RESULTS: In 165 patients, ASDAS ID was achieved by 47% at 1 year and 39% at 3 years; 36% and 33% achieved PSpARC remission, respectively. Sustained ASDAS ID and PSpARC remission were achieved by 52% (86/165) and 42% (70/165) of patients, respectively. Achieving ASDAS ID at week 12 significantly predicted 1 year (OR, 8.64 (95% CI 2.97 to 25.14)), 3 year (OR, 36.12 (95% CI 2.29 to 569.08)) and sustained ASDAS ID (OR, 8.01 (95% CI 2.47 to 25.97)); achieving PSpARC remission at week 12 consistently predicted 1 year (OR, 6.47 (95% CI 1.91 to 21.95)), 3 years (OR, 15.66 (95% CI 4.19 to 58.56)) and sustained PSpARC remission (OR, 20.27 (95% CI 5.37 to 76.46)). No baseline variables consistently predicted 1-year or 3-year remission or sustained remission. The safety profile of adalimumab was consistent with observations in other SpA disease indications. CONCLUSIONS: In patients with pSpA, early response to adalimumab, but not baseline demographics or disease characteristics, was a better predictor of long-term remission.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Van den Bosch F, Mease PJ, Sieper J, et al. Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2. RMD Open. 2018. PMID: 29531780. doi:10.1136/rmdopen-2017-000566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。